Guggenheim Securities adjusted its price target for Immunovant shares, listed on (NASDAQ:IMVT), to $44.00, a decrease from the previous $46.00, while sustaining a Buy rating on the stock. Currently ...

The researchers used the Paris criteria to reach a final diagnosis. A team of international researchers presented the rare case of a male patient with autoimmune hepatitis-primary biliary cholangitis ...

Future studies must aim to define strict diagnostic criteria for CIP and CIM, and to evaluate a range of interventions to prevent acquired polyneuropathy and myopathy in patients who are ...

Patients with COVID-19 who developed chronic inflammatory demyelinating polyneuropathy (CIDP) as a complication could follow a specific pattern in medical management, according to a study published in ...

Myelin is an insulating layer of lipids and proteins surrounding nerves. Myelin damage can cause problems with the nerves’ ability to send and receive electrical messages. Inflammatory disorders ...

Chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) is a progressive or relapsing neuropathy likely caused by an autoimmune attack on the peripheral nerves. A number of treatment ...

Guggenheim Securities updated their outlook on Immunovant (NASDAQ:IMVT) shares, raising the price target from $44.00 to $46.00 while maintaining a Buy rating on the stock. Currently trading at $23.23, ...

The criteria for assessing researchers for promotion to full professorship, and the incentives they foster vary widely around the world, says Yensi Flores Bueso, who has lived in all three countries.

CIDP treatment focuses on reducing and slowing the immune processes damaging your peripheral nervous system. It includes corticosteroids, intravenous immunoglobulin, and plasma exchange, but new ...

Riliprubart is under clinical development by Sanofi and currently in Phase III for Chronic Inflammatory Demyelinating Polyneuropathy (CIDP). According to GlobalData, Phase III drugs for Chronic ...

A free daily email with the biggest news stories of the day – and the best features from TheWeek.com Contact me with news and offers from other Future brands Receive email from us on behalf of ...

Background: Chronic inflammatory demyelinating polyradiculoneuropathy is a rare acquired immune-mediated progressive or relapsing disorder causing peripheral neuropathic disease of duration more ...